Sec. 2. Table of contents
260 words·~1 min read·
/bill/116/hr/987/eh/section-2A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
The table of contents of this Act is as follows: Sec. 1. Short title. Sec. 2. Table of contents. Title I—Lowering Prescription Drug Costs Subtitle A—Bringing low-Cost options and competition while keeping incentives for new generics Sec. 101. Change conditions of first generic exclusivity to spur access and competition. Subtitle B—Protecting consumer access to generic drugs Sec. 111. Unlawful agreements. Sec. 112. Notice and certification of agreements. Sec. 113. Forfeiture of 180-day exclusivity period.
Sec. 114. Commission litigation authority. Sec. 115. Statute of limitations. Subtitle C—Creating and restoring equal access to equivalent samples Sec. 121. Actions for delays of generic drugs and biosimilar biological products. Sec. 122. REMS approval process for subsequent filers. Sec. 123. Rule of construction. Subtitle D—Study on role of Federal assistance in drug development Sec. 131. Study on role of Federal assistance in drug development. Subtitle E—Pharmacy School Outreach Sec. 141.
Pharmacy school outreach. Subtitle F—Reports Sec. 151. Effects of increases in prescription drug price. Title II—Health Insurance Market Stabilization Sec. 201. Preserving State option to implement health care marketplaces. Sec. 202. Providing for additional requirements with respect to the navigator program. Sec. 203. Federal Exchange outreach and educational activities and annual enrollment targets. Sec. 204. Short-term limited duration insurance rule prohibition. Sec. 205.
Protection of health insurance coverage in certain Exchanges. Sec. 206. Sense of Congress relating to the practice of silver loading. Sec. 207. Consumer outreach, education, and assistance. Sec. 208. GAO report. Sec. 209. Report on the effects of website maintenance during open enrollment. Title III—Budgetary Effects Sec. 301. Determination of budgetary effects.